Akcea Therapeutics (AKCA) Tops Q3 EPS by 7c

Akcea Therapeutics (NASDAQ: AKCA) reported Q3 EPS of ($0.73), $0.07 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $19.24 million versus the consensus estimate of $16.82 million.

Akcea had $320 million of cash, cash equivalents and short-term investments as of September 30, 2018.

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M